VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

AAN 2022 | A pilot study of the effect of pharmacogenomic data on dosages of verapamil for migraine prevention

Yi-Chieh Chen, PharmD, Mayo Clinic, Rochester, MN, discusses a pilot study investigating the factors affecting the efficacy and safety of verapamil for migraine using pharmacogenomic reports in electronic medical records (EMRs). This retrospective study investigated 33 adult patients who had used verapamil for migraine and had a pharmacogenomic report in the EMRs. Results showed a wide range of minimum effective (range 20 to 320 mg) and maximum tolerable (range 20 to 480 mg) verapamil doses. The study also investigated six metabolic enzymes relevant to verapamil. Most patients were CYP1A2 rapid metabolizers, CYP2B6 intermediate metabolizers, and CYP3A4 normal metabolizers. There was a wide variety of CYP2C9, CYP2D6, and CYP3A5 phenotypes. However, after adjusting for age, sex, BMI, and smoking status, there was no association between different phenotypes and verapamil doses. The pilot study demonstrated that there was a wide range of minimum effective and maximum tolerable verapamil doses in patients with a variety of pharmacogenomic phenotypes in migraine prevention – however, the use of a small sample size and utilizing an existing pharmacogenomic report were limiting factors. This interview took place at the American Academy of Neurology 2022 Congress in Seattle, WA.